skip to main content

BSC – SEM 3 UNIT 5 PHARMACOLOGY

UNIT-5- Drugs used in treatment of Cardiovascular system and blood disorders

Introduction to Drugs Used in the Treatment of Cardiovascular System and Blood Disorders

Introduction

The cardiovascular system consists of the heart, blood vessels, and blood circulation, ensuring oxygen and nutrient delivery to tissues. Disorders of the cardiovascular system, such as hypertension, heart failure, angina, arrhythmias, and atherosclerosis, require pharmacological management to prevent complications like stroke and myocardial infarction.

The blood system is responsible for oxygen transport, clotting, and immune responses. Blood disorders, including anemia, clotting disorders (thrombosis, hemophilia), and hematological malignancies, require specific drugs for management.


1. Classification of Drugs Used in Cardiovascular and Blood Disorders

A. Drugs Acting on the Cardiovascular System

  1. Antihypertensive Drugs (Lower Blood Pressure)
    • Examples: Beta-blockers (Atenolol, Metoprolol), ACE inhibitors (Enalapril, Ramipril), ARBs (Losartan, Valsartan), Calcium channel blockers (Amlodipine, Diltiazem), Diuretics (Furosemide, Hydrochlorothiazide)
  2. Antianginal Drugs (Relieve Chest Pain)
    • Examples: Nitrates (Nitroglycerin, Isosorbide dinitrate), Beta-blockers, Calcium channel blockers
  3. Antiarrhythmic Drugs (Regulate Heart Rhythm)
    • Examples: Amiodarone, Lidocaine, Digoxin, Verapamil
  4. Heart Failure Medications (Improve Heart Function)
    • Examples: Diuretics, ACE inhibitors, Beta-blockers, Digoxin, Aldosterone antagonists
  5. Lipid-Lowering Drugs (Reduce Cholesterol & Prevent Atherosclerosis)
    • Examples: Statins (Atorvastatin, Rosuvastatin), Fibrates (Fenofibrate), Niacin, PCSK9 inhibitors

B. Drugs Acting on the Blood System

  1. Anticoagulants (Prevent Blood Clots)
    • Examples: Heparin, Warfarin, Direct oral anticoagulants (DOACs) like Apixaban, Dabigatran
  2. Antiplatelet Drugs (Prevent Platelet Aggregation & Thrombosis)
    • Examples: Aspirin, Clopidogrel, Ticagrelor
  3. Thrombolytics (Dissolve Clots in Stroke/Heart Attack)
    • Examples: Alteplase (tPA), Streptokinase, Urokinase
  4. Drugs for Anemia (Increase Red Blood Cell Production)
    • Examples: Iron supplements, Erythropoietin, Folic acid, Vitamin B12
  5. Drugs for Hematological Disorders (Treat Blood Cancers & Bleeding Disorders)
    • Examples: Hydroxyurea (Sickle Cell Anemia), Factor VIII (Hemophilia), Immunosuppressants for leukemia

2. Importance of Cardiovascular and Blood Disorder Medications

  • Reduce morbidity and mortality in heart disease and stroke.
  • Lower blood pressure and cholesterol levels, reducing heart attack risk.
  • Prevent and dissolve blood clots, preventing stroke and embolism.
  • Improve cardiac function in heart failure and arrhythmias.
  • Correct anemia and prevent complications of blood disorders.

Nurses play a critical role in administering, monitoring, and educating patients about cardiovascular and blood disorder drugs to ensure effective and safe therapy.

Pharmacology of Hematinics and Treatment of Anemia

Introduction

Hematinics are drugs that increase hemoglobin levels and red blood cell (RBC) production by supplying essential nutrients like iron, folic acid, and vitamin B12. They are used in the treatment of anemia, a condition characterized by low hemoglobin levels resulting in fatigue, weakness, pallor, and dyspnea.

Anemia can be classified as:

  • Iron Deficiency Anemia (IDA) – Due to lack of iron.
  • Megaloblastic Anemia – Due to vitamin B12 or folic acid deficiency.
  • Pernicious Anemia – Due to lack of intrinsic factor leading to vitamin B12 deficiency.
  • Hemolytic Anemia – Due to destruction of RBCs (sickle cell anemia, G6PD deficiency).
  • Aplastic Anemia – Due to bone marrow failure to produce RBCs.

1. Classification of Hematinics and Drugs for Anemia Treatment

A. Iron Supplements (For Iron Deficiency Anemia)

  • Examples: Ferrous sulfate, Ferrous fumarate, Ferric carboxymaltose, Iron dextran
  • Action: Increases hemoglobin production by replenishing iron stores.

B. Vitamin B12 Supplements (For Pernicious & Megaloblastic Anemia)

  • Examples: Cyanocobalamin, Hydroxocobalamin
  • Action: Essential for RBC formation and DNA synthesis.

C. Folic Acid (For Megaloblastic Anemia)

  • Examples: Folic acid, Leucovorin (Folinic Acid)
  • Action: Required for RBC maturation and fetal development in pregnancy.

D. Erythropoiesis-Stimulating Agents (For Anemia in Chronic Kidney Disease & Cancer)

  • Examples: Erythropoietin (Epoetin alfa, Darbepoetin alfa)
  • Action: Stimulates bone marrow to produce RBCs.

2. Pharmacology of Commonly Used Hematinics and Anemia Drugs

1. Ferrous Sulfate (Iron Supplement)

Composition

  • Ferrous sulfate (20% elemental iron)

Action

  • Replenishes iron stores in the body → Increases hemoglobin synthesis → Improves oxygen-carrying capacity.

Dosage and Route

  • Oral (Tablet/Syrup):
    • Adults: 150–200 mg of elemental iron daily.
    • Children: 3–6 mg/kg/day in divided doses.
  • Intravenous (Iron sucrose, Ferric carboxymaltose): 100–200 mg once or twice weekly.

Indications

  • Iron deficiency anemia (due to blood loss, pregnancy, malnutrition).
  • Anemia of chronic disease.

Contraindications

  • Hemochromatosis (iron overload disease).
  • Hemolytic anemia (can worsen RBC destruction).

Drug Interactions

  • Decreased absorption with calcium, antacids, and tetracyclines.
  • Increased effect with vitamin C (enhances iron absorption).

Side Effects

  • Nausea, vomiting, constipation, dark stools.

Adverse Effects

  • Gastrointestinal irritation, severe constipation.
  • Iron toxicity (if overdose occurs).

Toxicity

  • Overdose Symptoms: Severe vomiting, abdominal pain, diarrhea, metabolic acidosis.
  • Management: Deferoxamine (iron chelating agent), gastric lavage.

2. Cyanocobalamin (Vitamin B12 Supplement)

Composition

  • Cyanocobalamin, Hydroxocobalamin

Action

  • Essential for DNA synthesis and RBC maturation.

Dosage and Route

  • Oral (Mild Deficiency): 1000 mcg daily.
  • Intramuscular (Severe Deficiency/Pernicious Anemia): 1000 mcg every month.

Indications

  • Pernicious anemia (due to lack of intrinsic factor).
  • Megaloblastic anemia (due to vitamin B12 deficiency).
  • Neuropathy associated with vitamin B12 deficiency.

Contraindications

  • Uncorrected hypokalemia (B12 therapy can cause rapid RBC production leading to hypokalemia).

Drug Interactions

  • Reduced absorption with metformin, proton pump inhibitors (PPIs).

Side Effects

  • Headache, dizziness, nausea.

Adverse Effects

  • Hypokalemia (due to increased RBC production).

Toxicity

  • Overdose Symptoms: Skin rashes, itching, dizziness.
  • Management: Supportive care.

3. Folic Acid (Vitamin B9 Supplement)

Composition

  • Folic Acid, Leucovorin (Folinic Acid)

Action

  • Essential for DNA synthesis and RBC maturation.

Dosage and Route

  • Oral (Deficiency Treatment): 5 mg daily for 4 months.
  • Prevention in Pregnancy: 400 mcg daily.

Indications

  • Megaloblastic anemia (due to folic acid deficiency).
  • Prevention of neural tube defects in pregnancy.

Contraindications

  • Undiagnosed anemia (masks vitamin B12 deficiency).

Drug Interactions

  • Decreased effectiveness with phenytoin, sulfasalazine.

Side Effects

  • Nausea, rash.

Adverse Effects

  • Neurological damage if vitamin B12 deficiency is untreated.

Toxicity

  • Overdose Symptoms: Irritability, confusion.
  • Management: Supportive care.

4. Erythropoietin (Epoetin Alfa)

Composition

  • Recombinant human erythropoietin

Action

  • Stimulates bone marrow to increase RBC production.

Dosage and Route

  • Subcutaneous or IV Injection:
    • Chronic Kidney Disease (CKD): 50–100 IU/kg 3 times per week.
    • Cancer-Related Anemia: 150 IU/kg 3 times per week.

Indications

  • Anemia in chronic kidney disease (CKD).
  • Anemia due to chemotherapy.

Contraindications

  • Uncontrolled hypertension (risk of blood pressure increase).

Drug Interactions

  • Increased risk of thrombosis with iron therapy.

Side Effects

  • Hypertension, headache, fever.

Adverse Effects

  • Blood clots, stroke, polycythemia.

Toxicity

  • Overdose Symptoms: High BP, excessive RBC production.
  • Management: Adjust dose, bloodletting (phlebotomy).

3. Role of Nurse in Anemia Treatment

A. Assessment Before Administration

  • Monitor hemoglobin, hematocrit, and RBC levels before starting treatment.
  • Assess iron levels (serum ferritin, transferrin saturation).
  • Check vitamin B12 and folic acid levels in megaloblastic anemia.
  • Monitor BP and kidney function before giving erythropoietin.

B. Proper Drug Administration

  • Iron supplements should be taken on an empty stomach for better absorption.
  • Vitamin C enhances iron absorption.
  • Injectable iron must be given via deep IM or IV infusion to avoid reactions.
  • Monitor for signs of iron toxicity.

C. Patient Education

  • Teach patients to recognize anemia symptoms (fatigue, dizziness, pallor).
  • Encourage a diet rich in iron (meat, green leafy vegetables, beans).
  • Warn about constipation with iron supplements and recommend high-fiber intake.
  • Vitamin B12 is needed lifelong in pernicious anemia.

Pharmacology of Antiadrenergic Drugs

Introduction

Antiadrenergic drugs are medications that block the effects of adrenergic (sympathetic) stimulation by inhibiting the action of norepinephrine (NE) and epinephrine (adrenaline) on adrenergic receptors. These drugs are used to treat various cardiovascular, neurological, and endocrine disorders, including hypertension, arrhythmias, anxiety, and benign prostatic hyperplasia (BPH).

Antiadrenergic drugs are classified into alpha-blockers, beta-blockers, and centrally acting adrenergic inhibitors based on their site of action.


1. Classification of Antiadrenergic Drugs

A. Alpha-Adrenergic Blockers (Alpha-Blockers)

  • Block α1 or α2 adrenergic receptors, leading to vasodilation, decreased blood pressure, and improved urinary flow.
  • Examples:
    • Selective α1-blockers: Prazosin, Doxazosin, Tamsulosin (Used for hypertension and BPH).
    • Non-selective α-blockers: Phenoxybenzamine, Phentolamine (Used in pheochromocytoma).

B. Beta-Adrenergic Blockers (Beta-Blockers)

  • Block β1 and/or β2 adrenergic receptors, leading to reduced heart rate, cardiac output, and blood pressure.
  • Examples:
    • Cardioselective (β1-blockers): Atenolol, Metoprolol, Bisoprolol (Used for hypertension, heart failure).
    • Non-selective β-blockers: Propranolol, Nadolol, Timolol (Used for hypertension, migraines).
    • Alpha and beta-blockers: Labetalol, Carvedilol (Used for hypertensive emergencies, heart failure).

C. Centrally Acting Adrenergic Inhibitors

  • Reduce sympathetic outflow from the brain, leading to decreased blood pressure and heart rate.
  • Examples: Clonidine, Methyldopa, Reserpine (Used for hypertension).

2. Pharmacology of Commonly Used Antiadrenergic Drugs

1. Prazosin (Selective Alpha-1 Blocker)

Composition

  • Prazosin hydrochloride

Action

  • Blocks α1-receptorsVasodilationDecreased blood pressure.
  • Relaxes smooth muscles in the bladder and prostateImproves urine flow in BPH.

Dosage and Route

  • Oral (Hypertension): 1 mg once daily, increased gradually to 5–10 mg/day.
  • Oral (BPH): 0.5–2 mg twice daily.

Indications

  • Hypertension (especially in patients with BPH).
  • Benign prostatic hyperplasia (BPH).
  • Raynaud’s disease (to improve circulation).

Contraindications

  • Severe hypotension.
  • History of orthostatic hypotension (risk of syncope).

Drug Interactions

  • Increased hypotension with diuretics, beta-blockers, and alcohol.
  • May enhance the effect of PDE-5 inhibitors (e.g., Sildenafil).

Side Effects

  • Dizziness, headache, palpitations.

Adverse Effects

  • First-dose hypotension (risk of fainting).
  • Reflex tachycardia.

Toxicity

  • Overdose Symptoms: Severe hypotension, shock.
  • Management: IV fluids, vasopressors (e.g., norepinephrine).

2. Propranolol (Non-Selective Beta-Blocker)

Composition

  • Propranolol hydrochloride

Action

  • Blocks β1-receptors (in heart) → Decreases heart rate and cardiac output.
  • Blocks β2-receptors (in lungs and blood vessels) → Reduces tremors and anxiety.

Dosage and Route

  • Oral (Hypertension): 40–80 mg twice daily (Max: 320 mg/day).
  • Oral (Angina, Arrhythmias): 10–40 mg three times daily.
  • IV (Severe Tachycardia): 1 mg slow IV push, repeated every 2 minutes (Max: 10 mg).

Indications

  • Hypertension, angina, arrhythmias.
  • Migraine prophylaxis, essential tremors.
  • Anxiety, hyperthyroidism-related tachycardia.

Contraindications

  • Asthma and COPD (risk of bronchoconstriction).
  • Bradycardia, heart block (risk of heart failure).

Drug Interactions

  • Enhances effects of calcium channel blockers (bradycardia risk).
  • Reduced effect with NSAIDs (increased BP).

Side Effects

  • Fatigue, dizziness, cold extremities.

Adverse Effects

  • Bronchospasm (serious in asthmatics).
  • Bradycardia, hypotension.

Toxicity

  • Overdose Symptoms: Severe hypotension, bradycardia, heart failure.
  • Management: IV glucagon, atropine, dopamine.

3. Clonidine (Centrally Acting Adrenergic Inhibitor)

Composition

  • Clonidine hydrochloride

Action

  • Stimulates α2-receptors in the brainDecreases sympathetic outflowLowers blood pressure and heart rate.

Dosage and Route

  • Oral (Hypertension): 0.1–0.3 mg twice daily.
  • Transdermal Patch: Applied weekly (0.1–0.3 mg/day release).

Indications

  • Hypertension (especially in resistant cases).
  • Opioid withdrawal (to control withdrawal symptoms).
  • ADHD (as adjunct therapy).

Contraindications

  • Severe depression (risk of CNS depression).
  • Sudden discontinuation (causes rebound hypertension).

Drug Interactions

  • Enhances CNS depression with alcohol, sedatives.
  • Beta-blockers increase bradycardia risk.

Side Effects

  • Dry mouth, drowsiness, dizziness.

Adverse Effects

  • Rebound hypertension if stopped abruptly.

Toxicity

  • Overdose Symptoms: Severe drowsiness, hypotension, respiratory depression.
  • Management: IV fluids, vasopressors.

3. Role of Nurse in Antiadrenergic Drug Administration

A. Assessment Before Administration

  • Monitor blood pressure and heart rate before giving alpha or beta-blockers.
  • Assess for asthma or COPD before giving non-selective beta-blockers.
  • Check renal and hepatic function in elderly patients.

B. Proper Administration and Monitoring

  • Administer first dose of alpha-blockers at bedtime to avoid first-dose hypotension.
  • Do not stop beta-blockers suddenly (risk of rebound hypertension and angina).
  • Monitor for signs of bradycardia and hypotension.

C. Patient Education

  • Avoid alcohol and sedatives when taking centrally acting drugs (Clonidine).
  • Rise slowly from sitting or lying positions (to prevent postural hypotension).
  • Report symptoms of extreme fatigue, dizziness, or difficulty breathing.

4. Summary Table of Common Antiadrenergic Drugs

DrugClassMechanismIndicationsSide EffectsToxicity Management
Prazosinα1-blockerVasodilationHypertension, BPHHypotension, dizzinessIV fluids, vasopressors
PropranololNon-selective β-blocker↓ HR, ↓ BPHypertension, anxietyFatigue, bradycardiaIV glucagon, atropine
ClonidineCentrally acting α2-agonist↓ Sympathetic outputHypertension, ADHDDry mouth, drowsinessIV fluids, vasopressors

Pharmacology of Cholinergic and Anticholinergic Drugs

Introduction

Cholinergic drugs act by stimulating the parasympathetic nervous system (PNS) through acetylcholine (ACh) receptors, leading to increased secretions, smooth muscle contraction, and slowed heart rate. These drugs are used in conditions such as glaucoma, myasthenia gravis, and urinary retention.

Anticholinergic drugs inhibit the action of acetylcholine by blocking its receptors, leading to reduced secretions, bronchodilation, increased heart rate, and smooth muscle relaxation. They are used to treat asthma, Parkinson’s disease, bradycardia, and irritable bowel syndrome (IBS).


1. Classification of Cholinergic and Anticholinergic Drugs

A. Cholinergic Drugs (Parasympathomimetics)

  1. Direct-Acting Cholinergic Agonists
    • Examples: Bethanechol, Pilocarpine, Carbachol
    • Action: Bind directly to muscarinic or nicotinic receptors to stimulate PNS activity.
  2. Indirect-Acting Cholinergic Agonists (Cholinesterase Inhibitors)
    • Examples: Neostigmine, Pyridostigmine, Rivastigmine, Donepezil
    • Action: Inhibit acetylcholinesterase, increasing acetylcholine levels.

B. Anticholinergic Drugs (Parasympatholytics)

  1. Muscarinic Receptor Blockers (Used for bronchodilation, bradycardia, motion sickness, and GI disorders)
    • Examples: Atropine, Ipratropium, Tiotropium, Scopolamine, Oxybutynin
  2. Nicotinic Receptor Blockers (Used in anesthesia and muscle relaxation)
    • Examples: Pancuronium, Vecuronium, Succinylcholine

2. Pharmacology of Commonly Used Cholinergic and Anticholinergic Drugs

1. Bethanechol (Direct-Acting Cholinergic Agonist)

Composition

  • Bethanechol chloride

Action

  • Stimulates muscarinic receptors, leading to bladder contraction and increased peristalsis.

Dosage and Route

  • Oral: 10–50 mg 3–4 times daily.

Indications

  • Urinary retention (non-obstructive).
  • Postoperative ileus (to stimulate bowel movements).

Contraindications

  • Asthma (risk of bronchoconstriction).
  • Peptic ulcer (stimulates gastric acid secretion).

Drug Interactions

  • Increased effects with cholinesterase inhibitors (risk of excessive PNS activation).

Side Effects

  • Nausea, sweating, increased urination.

Adverse Effects

  • Severe bradycardia, hypotension, bronchospasm.

Toxicity

  • Overdose Symptoms: Excessive salivation, diarrhea, hypotension.
  • Management: Atropine (antidote), supportive care.

2. Neostigmine (Indirect-Acting Cholinergic Agonist)

Composition

  • Neostigmine methylsulfate

Action

  • Inhibits acetylcholinesterase, increasing acetylcholine levels in neuromuscular junctions.

Dosage and Route

  • Oral: 15–30 mg every 3–4 hours.
  • IV (Myasthenia Gravis Crisis): 0.5–2.5 mg slow IV push.

Indications

  • Myasthenia gravis (to improve muscle strength).
  • Reversal of neuromuscular blockade.

Contraindications

  • Gastrointestinal or urinary obstruction.

Drug Interactions

  • Increased effects with beta-blockers (risk of severe bradycardia).

Side Effects

  • Abdominal cramps, diarrhea, sweating.

Adverse Effects

  • Cholinergic crisis (excessive PNS activation).

Toxicity

  • Overdose Symptoms: Muscle weakness, respiratory failure.
  • Management: Atropine (antidote), ventilatory support.

3. Atropine (Anticholinergic Drug – Muscarinic Blocker)

Composition

  • Atropine sulfate

Action

  • Blocks muscarinic receptors, leading to increased heart rate, reduced secretions, and bronchodilation.

Dosage and Route

  • IV (Bradycardia): 0.5 mg IV every 3–5 minutes (Max: 3 mg).
  • IM (Pre-anesthesia): 0.4–0.6 mg 30–60 min before surgery.

Indications

  • Bradycardia (to increase heart rate).
  • Preoperative secretion reduction.
  • Antidote for organophosphate poisoning.

Contraindications

  • Glaucoma (increases intraocular pressure).
  • Urinary retention (worsens obstruction).

Drug Interactions

  • Increased effects with antihistamines, tricyclic antidepressants.

Side Effects

  • Dry mouth, blurred vision, constipation.

Adverse Effects

  • Severe tachycardia, hallucinations, acute urinary retention.

Toxicity

  • Overdose Symptoms: Hyperthermia, severe confusion, hallucinations.
  • Management: Physostigmine (antidote), cooling measures.

4. Ipratropium (Anticholinergic Drug – Bronchodilator)

Composition

  • Ipratropium bromide

Action

  • Blocks muscarinic receptors in the lungs, leading to bronchodilation and reduced mucus secretion.

Dosage and Route

  • Inhalation (MDI/Nebulizer): 20–40 mcg every 6–8 hours.

Indications

  • COPD, asthma (for bronchodilation).

Contraindications

  • Glaucoma, prostatic hyperplasia.

Drug Interactions

  • Enhances effects of beta-2 agonists (synergistic bronchodilation).

Side Effects

  • Dry mouth, cough, blurred vision.

Adverse Effects

  • Paradoxical bronchospasm, urinary retention.

Toxicity

  • Overdose Symptoms: Tachycardia, confusion.
  • Management: Supportive care.

3. Role of Nurse in Cholinergic and Anticholinergic Drug Administration

A. Assessment Before Administration

  • Monitor vital signs (BP, HR, RR) before giving cholinergic or anticholinergic drugs.
  • Assess bowel and bladder function before giving cholinergics.
  • Check for history of glaucoma or urinary retention before giving anticholinergics.

B. Proper Administration and Monitoring

  • Administer cholinergic drugs before meals to improve absorption.
  • Ensure proper inhalation technique for Ipratropium (rinse mouth after use).
  • Monitor for signs of cholinergic crisis (excessive salivation, muscle weakness).

C. Patient Education

  • Avoid driving after taking anticholinergics (causes drowsiness).
  • Drink plenty of fluids when taking anticholinergics (reduces dry mouth).
  • Report signs of excessive sweating, diarrhea (signs of cholinergic toxicity).

4. Summary Table of Common Cholinergic and Anticholinergic Drugs

DrugClassMechanismIndicationsSide EffectsToxicity Management
BethanecholCholinergic agonistStimulates bladder contractionUrinary retentionNausea, sweatingAtropine (antidote)
AtropineAnticholinergicBlocks muscarinic receptorsBradycardia, pre-anesthesiaDry mouth, tachycardiaPhysostigmine (antidote)
IpratropiumAnticholinergicBronchodilationCOPD, asthmaDry mouth, coughSupportive care

Pharmacology of Adrenergic Drugs for Congestive Heart Failure (CHF) and Vasodilators

Introduction

Congestive Heart Failure (CHF) is a condition in which the heart fails to pump blood efficiently, leading to fluid retention, shortness of breath, and fatigue. The goal of treatment is to improve cardiac output, reduce preload and afterload, and enhance myocardial function.

Adrenergic drugs (sympathomimetics) and vasodilators play key roles in managing CHF by stimulating the heart or relaxing blood vessels to improve circulation.


1. Classification of Adrenergic Drugs for CHF and Vasodilators

A. Adrenergic Drugs for CHF (Positive Inotropes)

  1. Beta-1 Adrenergic Agonists (Increase Heart Contractility)
    • Examples: Dobutamine, Dopamine
    • Action: Increase cardiac output by stimulating beta-1 receptors in the heart.
  2. Alpha and Beta Adrenergic Agonists (Increase Blood Pressure and Perfusion)
    • Examples: Norepinephrine, Epinephrine
    • Action: Vasoconstriction (α-effects) and increased heart rate/contractility (β-effects).

B. Vasodilators (Reduce Cardiac Workload and Improve Blood Flow)

  1. Nitrates (Venous and Arterial Vasodilators)
    • Examples: Nitroglycerin, Isosorbide Dinitrate
    • Action: Reduce preload, decrease myocardial oxygen demand.
  2. Direct Arterial Vasodilators (Reduce Afterload)
    • Examples: Hydralazine, Minoxidil
    • Action: Decrease systemic vascular resistance, lowering afterload.
  3. ACE Inhibitors (Vasodilators and Neurohormonal Modulators)
    • Examples: Enalapril, Lisinopril, Ramipril
    • Action: Block angiotensin II formation, reducing vasoconstriction and fluid retention.
  4. Angiotensin II Receptor Blockers (ARBs) (Alternative to ACE Inhibitors)
    • Examples: Losartan, Valsartan
    • Action: Prevent angiotensin II-mediated vasoconstriction.
  5. Phosphodiesterase Inhibitors (Increase Cardiac Output and Vasodilation)
    • Examples: Milrinone, Inamrinone
    • Action: Increase cAMP levels, leading to stronger heart contractions and vasodilation.

2. Pharmacology of Commonly Used Adrenergic Drugs for CHF and Vasodilators

1. Dobutamine (Beta-1 Adrenergic Agonist)

Composition

  • Dobutamine hydrochloride

Action

  • Stimulates β1-receptorsIncreases heart contractility and cardiac output.

Dosage and Route

  • IV Infusion: 2–20 mcg/kg/min (adjusted based on patient response).

Indications

  • Acute decompensated heart failure
  • Cardiogenic shock

Contraindications

  • Severe hypotension without adequate fluid resuscitation.
  • Ventricular arrhythmias (may worsen tachycardia).

Drug Interactions

  • Increased risk of arrhythmias with beta-blockers or digoxin.

Side Effects

  • Hypertension, tachycardia, palpitations.

Adverse Effects

  • Severe arrhythmias, myocardial ischemia.

Toxicity

  • Overdose Symptoms: Severe hypertension, tachycardia, myocardial infarction.
  • Management: Beta-blockers (for tachycardia), IV fluids (for hypotension).

2. Dopamine (Alpha and Beta Adrenergic Agonist)

Composition

  • Dopamine hydrochloride

Action

  • Low dose (1–3 mcg/kg/min): Dilates renal blood vessels → Improves kidney perfusion.
  • Medium dose (3–10 mcg/kg/min): Stimulates β1 receptors → Increases cardiac output.
  • High dose (>10 mcg/kg/min): Stimulates α-receptors → Causes vasoconstriction and increased BP.

Dosage and Route

  • IV Infusion: 2–20 mcg/kg/min (titrated based on response).

Indications

  • Cardiogenic shock, acute heart failure.
  • Septic shock (to maintain BP).

Contraindications

  • Pheochromocytoma (risk of severe hypertension).
  • Uncontrolled arrhythmias.

Drug Interactions

  • Increased vasoconstriction with MAO inhibitors.

Side Effects

  • Tachycardia, headache, nausea.

Adverse Effects

  • Arrhythmias, excessive vasoconstriction.

Toxicity

  • Overdose Symptoms: Severe hypertension, necrosis at IV site.
  • Management: Phentolamine (for extravasation), beta-blockers for tachycardia.

3. Nitroglycerin (Nitrate Vasodilator)

Composition

  • Nitroglycerin (Glyceryl trinitrate)

Action

  • Dilates veins and arteries → Reduces preload and myocardial oxygen demand.

Dosage and Route

  • Sublingual (Acute Angina): 0.3–0.6 mg every 5 minutes (Max: 3 doses).
  • IV (Heart Failure): 5–100 mcg/min infusion.

Indications

  • Acute heart failure, angina, hypertensive crisis.

Contraindications

  • Severe hypotension, increased intracranial pressure.

Drug Interactions

  • Severe hypotension with sildenafil (PDE-5 inhibitors).

Side Effects

  • Headache, dizziness, flushing.

Adverse Effects

  • Severe hypotension, reflex tachycardia.

Toxicity

  • Overdose Symptoms: Methemoglobinemia, severe hypotension.
  • Management: Oxygen therapy, IV fluids, methylene blue (for methemoglobinemia).

4. Hydralazine (Direct Arterial Vasodilator)

Composition

  • Hydralazine hydrochloride

Action

  • Dilates arterioles → Reduces afterload and systemic vascular resistance.

Dosage and Route

  • Oral: 10–50 mg four times daily.
  • IV (Severe Hypertension/Heart Failure): 10–20 mg IV every 4–6 hours.

Indications

  • Hypertension, CHF (especially in African American patients with nitrate therapy).

Contraindications

  • Severe coronary artery disease (risk of angina exacerbation).

Drug Interactions

  • Enhanced hypotension with diuretics and beta-blockers.

Side Effects

  • Headache, nausea, tachycardia.

Adverse Effects

  • Lupus-like syndrome (long-term use).

Toxicity

  • Overdose Symptoms: Severe hypotension, shock.
  • Management: IV fluids, vasopressors.

3. Role of Nurse in Adrenergic and Vasodilator Drug Administration

A. Patient Assessment Before Administration

  • Monitor BP, HR, and ECG before giving adrenergic drugs or vasodilators.
  • Assess signs of fluid overload in CHF patients.
  • Check renal function before dopamine administration.

B. Proper Administration and Monitoring

  • Administer IV adrenergic drugs through central lines (to avoid extravasation).
  • Titrate vasodilator infusion based on BP and symptoms.
  • Monitor for headache and dizziness with nitrates.

C. Patient Education

  • Avoid sudden posture changes after vasodilators (to prevent falls).
  • Report chest pain or palpitations after adrenergic drug use.
  • Do not mix nitrates with sildenafil (risk of severe hypotension).

Pharmacology of Anti-Anginal Drugs

Introduction

Angina pectoris is chest pain caused by reduced blood flow (ischemia) to the heart muscle, often due to coronary artery disease (CAD). Anti-anginal drugs reduce myocardial oxygen demand, improve blood flow to the heart, and relieve chest pain.


1. Classification of Anti-Anginal Drugs

A. Nitrates (Vasodilators)

  • Examples: Nitroglycerin, Isosorbide Dinitrate, Isosorbide Mononitrate
  • Action: Dilate veins and arteries, reducing preload and myocardial oxygen demand.

B. Beta-Blockers (Reduce Heart Workload)

  • Examples: Atenolol, Metoprolol, Propranolol
  • Action: Block beta-1 receptors, reducing heart rate and oxygen demand.

C. Calcium Channel Blockers (Increase Blood Flow)

  • Examples: Amlodipine, Diltiazem, Verapamil
  • Action: Relax coronary arteries, improve oxygen supply, and reduce heart workload.

D. Metabolic Modulators (Improve Heart Efficiency)

  • Examples: Ranolazine (Ranolaz)
  • Action: Reduce sodium entry into heart cells, improving oxygen use.

2. Pharmacology of Common Anti-Anginal Drugs

1. Nitroglycerin (Nitrate Vasodilator)

Composition

  • Nitroglycerin (Glyceryl trinitrate)

Action

  • Dilates veins and arteries → Decreases preload → Reduces myocardial oxygen demand.

Dosage and Route

  • Sublingual (Acute Angina): 0.3–0.6 mg every 5 minutes (Max: 3 doses).
  • IV (Severe Angina/Heart Failure): 5–100 mcg/min infusion.

Indications

  • Acute and chronic angina.
  • Hypertensive crisis.

Contraindications

  • Severe hypotension, increased intracranial pressure.

Drug Interactions

  • Severe hypotension with sildenafil (PDE-5 inhibitors).

Side Effects

  • Headache, dizziness, flushing.

Adverse Effects

  • Severe hypotension, reflex tachycardia.

Toxicity

  • Overdose Symptoms: Methemoglobinemia, severe hypotension.
  • Management: Oxygen therapy, IV fluids, methylene blue.

2. Metoprolol (Beta-Blocker)

Composition

  • Metoprolol Tartrate/Succinate

Action

  • Blocks β1-receptorsSlows heart rate, reduces contractility, and decreases oxygen demand.

Dosage and Route

  • Oral (Stable Angina): 50–100 mg twice daily.
  • IV (Acute Angina/MI): 5 mg IV every 5 minutes (Max: 15 mg).

Indications

  • Chronic stable angina, hypertension, post-myocardial infarction.

Contraindications

  • Bradycardia, heart block, asthma.

Drug Interactions

  • Enhanced bradycardia with calcium channel blockers.

Side Effects

  • Fatigue, dizziness, bradycardia.

Adverse Effects

  • Heart failure, bronchospasm (in asthma patients).

Toxicity

  • Overdose Symptoms: Severe bradycardia, hypotension.
  • Management: IV glucagon, atropine, fluids.

3. Amlodipine (Calcium Channel Blocker)

Composition

  • Amlodipine Besylate

Action

  • Blocks calcium channels in vascular smooth muscleVasodilation, reduced afterload, and improved coronary blood flow.

Dosage and Route

  • Oral (Chronic Angina/Hypertension): 5–10 mg once daily.

Indications

  • Chronic stable angina, hypertension, Prinzmetal’s angina.

Contraindications

  • Severe aortic stenosis, heart failure with reduced ejection fraction.

Drug Interactions

  • Enhanced hypotension with beta-blockers.

Side Effects

  • Peripheral edema, headache, flushing.

Adverse Effects

  • Hypotension, reflex tachycardia.

Toxicity

  • Overdose Symptoms: Severe hypotension, bradycardia.
  • Management: IV fluids, calcium gluconate.

4. Ranolazine (Metabolic Modulator)

Composition

  • Ranolazine

Action

  • Inhibits late sodium current in cardiac cells → Improves oxygen efficiency.

Dosage and Route

  • Oral (Chronic Angina): 500–1000 mg twice daily.

Indications

  • Chronic stable angina (as adjunct therapy).

Contraindications

  • QT prolongation, severe liver disease.

Drug Interactions

  • QT prolongation risk with amiodarone.

Side Effects

  • Dizziness, constipation, headache.

Adverse Effects

  • Severe QT prolongation, arrhythmias.

Toxicity

  • Overdose Symptoms: Arrhythmias, hypotension.
  • Management: ECG monitoring, IV magnesium.

3. Role of Nurse in Anti-Anginal Drug Administration

A. Patient Assessment Before Administration

  • Monitor BP, HR, and ECG before giving anti-anginal drugs.
  • Assess chest pain characteristics (onset, duration, triggers).
  • Check renal and liver function before ranolazine therapy.

B. Proper Administration and Monitoring

  • Instruct patients to sit or lie down before taking nitroglycerin (prevents fainting).
  • Monitor for bradycardia and hypotension with beta-blockers and calcium channel blockers.
  • Do not crush extended-release tablets (ranolazine, metoprolol).

C. Patient Education

  • Take sublingual nitroglycerin at first sign of chest pain.
  • Avoid sildenafil (Viagra) while taking nitrates (severe hypotension risk).
  • Rise slowly after taking calcium channel blockers to avoid dizziness.
  • Report persistent chest pain despite medication use.

4. Summary Table of Common Anti-Anginal Drugs

DrugClassMechanismIndicationsSide EffectsToxicity Management
NitroglycerinNitrateVasodilation, ↓ PreloadAcute & chronic anginaHeadache, flushingIV fluids, methylene blue
MetoprololBeta-Blocker↓ HR, ↓ BP, ↓ O2 demandChronic angina, HTNFatigue, bradycardiaIV glucagon, atropine
AmlodipineCalcium Channel BlockerVasodilationChronic angina, HTNEdema, headacheIV calcium gluconate
RanolazineMetabolic ModulatorImproves oxygen efficiencyChronic stable anginaQT prolongation, dizzinessECG monitoring, IV Mg++

Antiarrhythmics.

Antiarrhythmic drugs are used to manage and treat cardiac arrhythmias, which are abnormal heart rhythms resulting from disturbances in the electrical conduction system of the heart. They work by modifying ion channel activity and conduction pathways in cardiac tissue.


1. Classification of Antiarrhythmic Drugs (Vaughan-Williams Classification)

ClassTypeExamplesMechanism of Action
Class ISodium Channel BlockersLidocaine, Procainamide, FlecainideBlock sodium channels, reduce excitability, and slow conduction
Class IIBeta-BlockersPropranolol, Metoprolol, AtenololDecrease heart rate, reduce excitability, and inhibit sympathetic stimulation
Class IIIPotassium Channel BlockersAmiodarone, Sotalol, DofetilideProlong repolarization and action potential duration
Class IVCalcium Channel BlockersVerapamil, DiltiazemSlow conduction at the AV node and reduce heart rate
UnclassifiedMiscellaneous AgentsDigoxin, Adenosine, Magnesium SulfateAffect ion exchange, AV node conduction, or atrial tissue activity

2. Composition of Antiarrhythmic Drugs

Each antiarrhythmic drug has different active ingredients based on its class. Below are a few examples:

  • Lidocaine (Class Ib): Contains lidocaine hydrochloride
  • Amiodarone (Class III): Contains iodine compounds affecting potassium channels
  • Propranolol (Class II): A non-selective beta-blocker
  • Verapamil (Class IV): A calcium channel blocker

3. Mechanism of Action

  • Class I (Na+ Channel Blockers): Reduce the rate of depolarization by blocking sodium influx into myocardial cells.
  • Class II (Beta-Blockers): Reduce sympathetic stimulation, slow down the heart rate, and decrease conduction velocity.
  • Class III (K+ Channel Blockers): Prolong action potential duration and refractory period.
  • Class IV (Ca2+ Channel Blockers): Slow AV node conduction and decrease heart rate.
  • Miscellaneous Drugs:
    • Adenosine: Temporarily blocks AV conduction.
    • Digoxin: Increases vagal activity and slows AV node conduction.

4. Dosage and Routes of Administration

DrugDosageRoute
LidocaineIV bolus: 50-100 mg, followed by infusion 1-4 mg/minIV
AmiodaroneIV: 150 mg over 10 min, then 1 mg/min for 6 hrs, Oral: 200-400 mg/dayIV, Oral
PropranololIV: 1-3 mg, Oral: 10-40 mg 3-4 times dailyIV, Oral
VerapamilIV: 2.5-10 mg every 15-30 min, Oral: 80-120 mg 3 times/dayIV, Oral
AdenosineIV bolus: 6 mg rapid push, repeat 12 mg if neededIV

5. Indications

  • Class I: Ventricular tachycardia, atrial fibrillation, supraventricular tachycardia (SVT)
  • Class II: Atrial fibrillation, ventricular arrhythmias, post-MI arrhythmias
  • Class III: Life-threatening ventricular arrhythmias, atrial fibrillation
  • Class IV: SVT, atrial fibrillation with rapid ventricular response
  • Adenosine: SVT
  • Digoxin: Atrial fibrillation, heart failure

6. Contraindications

  • Class I: Heart block, severe bradycardia, cardiogenic shock
  • Class II: Asthma, severe bradycardia, AV block, decompensated heart failure
  • Class III: Severe liver disease, thyroid dysfunction (Amiodarone)
  • Class IV: Severe heart failure, hypotension, AV block
  • Adenosine: AV block, bronchospasm disorders
  • Digoxin: Ventricular fibrillation, AV block without pacemaker

7. Drug Interactions

DrugInteracting DrugEffect
AmiodaroneWarfarin, DigoxinIncreases levels, risk of toxicity
Beta-BlockersCalcium Channel BlockersSevere bradycardia, hypotension
LidocainePhenytoinIncreased risk of CNS toxicity
VerapamilDigoxinIncreases digoxin levels
AdenosineTheophyllineReduced effectiveness

8. Side Effects

Drug ClassCommon Side Effects
Class IDizziness, nausea, blurred vision
Class IIFatigue, bradycardia, hypotension
Class IIIThyroid dysfunction, liver toxicity, photosensitivity
Class IVConstipation, dizziness, hypotension
MiscellaneousDigoxin toxicity (nausea, visual disturbances), Adenosine (flushing, chest pain)

9. Adverse Effects & Toxicity

  • Lidocaine toxicity: CNS effects (tremors, seizures, confusion)
  • Amiodarone toxicity: Pulmonary fibrosis, thyroid dysfunction, liver toxicity
  • Beta-blocker overdose: Severe bradycardia, hypotension, bronchospasm
  • Calcium channel blocker overdose: Severe hypotension, AV block
  • Digoxin toxicity: Nausea, vomiting, yellow vision (halos), cardiac arrhythmias

10. Role of the Nurse

Before Administration

Assess:

  • ECG monitoring for arrhythmias
  • Baseline vitals (BP, HR)
  • Electrolyte levels (K+, Mg2+)
  • Liver and kidney function tests

During Administration

Monitor:

  • ECG changes for signs of effectiveness or toxicity
  • Blood pressure and heart rate frequently
  • Signs of worsening arrhythmia

After Administration

Evaluate:

  • Therapeutic response (normal rhythm)
  • Watch for adverse effects (bradycardia, hypotension, dizziness)
  • Educate the patient on symptoms of toxicity (nausea, vision changes)

Patient Education

  • Take medications at the same time daily
  • Report dizziness, palpitations, vision changes immediately
  • Avoid grapefruit juice (interferes with metabolism of some drugs)
  • Importance of regular ECG and blood tests

Antihypertensives

Antihypertensive drugs are used to manage hypertension (high blood pressure) by targeting different physiological mechanisms to lower blood pressure and reduce the risk of complications such as stroke, heart attack, and kidney disease.


1. Classification of Antihypertensive Drugs

ClassExamplesMechanism of Action
1. DiureticsHydrochlorothiazide, Furosemide, SpironolactoneIncrease urine output, reduce blood volume
2. Beta-BlockersPropranolol, Atenolol, MetoprololBlock β-receptors, reduce heart rate and cardiac output
3. Calcium Channel Blockers (CCBs)Amlodipine, Verapamil, DiltiazemBlock calcium channels, relax blood vessels
4. Angiotensin-Converting Enzyme (ACE) InhibitorsEnalapril, Lisinopril, RamiprilBlock conversion of Angiotensin I to II, reducing vasoconstriction
5. Angiotensin II Receptor Blockers (ARBs)Losartan, Valsartan, TelmisartanBlock angiotensin II receptors, preventing vasoconstriction
6. Alpha-BlockersPrazosin, DoxazosinBlock alpha-receptors, reducing peripheral resistance
7. Centrally Acting AgentsClonidine, MethyldopaReduce sympathetic output, lowering BP
8. Direct VasodilatorsHydralazine, MinoxidilDirectly relax vascular smooth muscle

2. Composition of Antihypertensive Drugs

Each antihypertensive drug has different active ingredients. Some examples:

  • Amlodipine (CCB): Active ingredient – Amlodipine besylate
  • Lisinopril (ACE Inhibitor): Active ingredient – Lisinopril dihydrate
  • Losartan (ARB): Active ingredient – Losartan potassium
  • Hydrochlorothiazide (Diuretic): Active ingredient – Hydrochlorothiazide

3. Mechanism of Action

  • Diuretics: Reduce blood volume by increasing urine output.
  • Beta-Blockers: Reduce cardiac workload by decreasing heart rate and contractility.
  • CCBs: Relax arterial smooth muscle, leading to vasodilation.
  • ACE Inhibitors: Prevent angiotensin II formation, reducing vasoconstriction.
  • ARBs: Block angiotensin II effects, causing vasodilation.
  • Alpha-Blockers: Reduce sympathetic vasoconstriction.
  • Centrally Acting Agents: Reduce sympathetic nervous system activity.
  • Direct Vasodilators: Act on vascular smooth muscle to cause dilation.

4. Dosage and Routes of Administration

DrugDosageRoute
Amlodipine5–10 mg once dailyOral
Lisinopril5–40 mg once dailyOral
Losartan25–100 mg once dailyOral
Hydrochlorothiazide12.5–50 mg once dailyOral
Propranolol20–80 mg twice dailyOral
Clonidine0.1–0.3 mg twice dailyOral, Transdermal
Hydralazine10–50 mg three times dailyOral, IV

5. Indications

  • Hypertension (primary and secondary)
  • Heart failure (ACE inhibitors, ARBs, beta-blockers)
  • Post-myocardial infarction (beta-blockers, ACE inhibitors)
  • Chronic kidney disease (ACE inhibitors, ARBs)
  • Angina (Calcium channel blockers, beta-blockers)
  • Hypertensive crisis (IV vasodilators, alpha-agonists)

6. Contraindications

  • Diuretics: Severe renal failure, electrolyte imbalance
  • Beta-Blockers: Asthma, severe bradycardia, heart block
  • CCBs: Severe heart failure, hypotension
  • ACE Inhibitors: Pregnancy, history of angioedema
  • ARBs: Pregnancy, severe renal impairment
  • Alpha-Blockers: Orthostatic hypotension
  • Centrally Acting Agents: Depression, liver disease
  • Direct Vasodilators: Severe coronary artery disease

7. Drug Interactions

DrugInteracting DrugEffect
ACE InhibitorsPotassium supplementsHyperkalemia
Beta-BlockersVerapamil, DiltiazemSevere bradycardia, hypotension
DiureticsNSAIDsReduced diuretic effect
ARBsLithiumIncreased lithium toxicity
CCBsGrapefruit juiceIncreased drug concentration

8. Side Effects

Drug ClassCommon Side Effects
DiureticsDehydration, electrolyte imbalance
Beta-BlockersFatigue, bradycardia, dizziness
CCBsSwelling, constipation, headache
ACE InhibitorsDry cough, angioedema, hyperkalemia
ARBsDizziness, kidney dysfunction
Alpha-BlockersPostural hypotension
Centrally Acting AgentsDrowsiness, dry mouth
VasodilatorsHeadache, reflex tachycardia

9. Adverse Effects & Toxicity

  • ACE Inhibitors: Angioedema, severe hyperkalemia
  • Beta-Blockers: Bradycardia, heart failure exacerbation
  • CCBs: Severe hypotension, cardiac depression
  • Diuretics: Severe dehydration, hypokalemia
  • Centrally Acting Agents: Rebound hypertension
  • Direct Vasodilators: Fluid retention, tachycardia

10. Role of the Nurse

Before Administration

Assess:

  • Blood pressure and heart rate
  • Electrolyte levels (Na+, K+)
  • Kidney function (Creatinine, GFR)
  • History of cardiovascular disease

During Administration

Monitor:

  • BP response
  • Signs of dizziness or hypotension
  • Fluid balance (diuretics)
  • ECG for arrhythmias

After Administration

Evaluate:

  • Therapeutic response (BP control)
  • Monitor for side effects (cough, swelling, dizziness)
  • Educate patient about adherence

Patient Education

  • Take medications at the same time daily.
  • Avoid sudden position changes to prevent dizziness.
  • Report swelling, persistent cough, or dizziness to healthcare providers.
  • Avoid excessive salt and alcohol intake.
  • Diuretics: Increase potassium intake (except for potassium-sparing diuretics).
  • ACE inhibitors/ARBs: Avoid potassium-rich foods.
  • Beta-blockers: Do not stop suddenly to prevent rebound hypertension.
  • Calcium channel blockers: Avoid grapefruit juice.

Coagulants & Anticoagulants:

1. Introduction

  • Coagulants are drugs that promote blood clotting and are used to manage bleeding disorders.
  • Anticoagulants are drugs that prevent blood clotting and are used to treat and prevent thromboembolic disorders.

2. Classification of Coagulants & Anticoagulants

A. Coagulants (Pro-Coagulants)

ClassExamplesMechanism of Action
Vitamin K AnalogsPhytomenadione (Vitamin K1), Menadione (Vitamin K3)Helps in the synthesis of clotting factors (II, VII, IX, X) in the liver
Fibrinolytic InhibitorsAminocaproic Acid, Tranexamic AcidInhibits plasminogen activation, preventing clot breakdown
Blood DerivativesFresh Frozen Plasma (FFP), Cryoprecipitate, Platelet ConcentrateProvides clotting factors and platelets directly
Thrombin & Fibrinogen AgentsFibrin Sealants, Topical ThrombinEnhances clot formation at bleeding sites

B. Anticoagulants (Blood Thinners)

ClassExamplesMechanism of Action
Parenteral AnticoagulantsHeparin, Low Molecular Weight Heparin (LMWH) – Enoxaparin, DalteparinInhibits thrombin and factor Xa
Oral Anticoagulants (Vitamin K Antagonists)Warfarin, AcenocoumarolInhibits synthesis of vitamin K-dependent clotting factors
Direct Thrombin Inhibitors (DTIs)Dabigatran, ArgatrobanDirectly inhibits thrombin (Factor IIa)
Direct Factor Xa InhibitorsRivaroxaban, Apixaban, EdoxabanInhibits Factor Xa, preventing clot formation

3. Composition of Coagulants & Anticoagulants

DrugActive Ingredient
Vitamin K1 (Phytomenadione)Fat-soluble Vitamin K derivative
Tranexamic AcidSynthetic lysine analog
HeparinSulfated polysaccharide from animal sources
WarfarinSynthetic coumarin derivative
RivaroxabanSelective Factor Xa inhibitor

4. Mechanism of Action

A. Coagulants (Pro-Coagulants)

  • Vitamin K: Increases production of clotting factors in the liver.
  • Tranexamic Acid: Prevents fibrin breakdown (antifibrinolytic).
  • Platelet Concentrates: Provide platelets to enhance clot formation.

B. Anticoagulants

  • Heparin: Inhibits thrombin and Factor Xa, preventing clot formation.
  • Warfarin: Blocks vitamin K-dependent clotting factors, reducing coagulation.
  • Dabigatran: Directly inhibits thrombin (Factor IIa), preventing fibrin formation.
  • Rivaroxaban: Selectively inhibits Factor Xa, stopping clot formation.

5. Dosage and Routes of Administration

DrugDosageRoute
Vitamin K12.5–10 mgIV, Oral, SC
Tranexamic Acid500–1000 mg every 8 hoursIV, Oral
Heparin5000–10,000 IU bolus, then infusionIV, SC
Enoxaparin (LMWH)40 mg once dailySC
Warfarin2–10 mg dailyOral
Dabigatran110–150 mg twice dailyOral
Rivaroxaban10–20 mg once dailyOral

6. Indications

A. Coagulants

  • Vitamin K Deficiency
  • Warfarin Overdose
  • Hemophilia (Plasma-derived clotting factors)
  • Post-Surgery Bleeding
  • Traumatic Bleeding

B. Anticoagulants

  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Atrial Fibrillation (to prevent stroke)
  • Prosthetic Heart Valves (Warfarin)
  • Myocardial Infarction (Heparin, LMWH)
  • Post-Surgical Thromboprophylaxis (Dabigatran, Rivaroxaban)

7. Contraindications

DrugContraindications
Vitamin KSevere liver disease, hypersensitivity
Tranexamic AcidDIC (Disseminated Intravascular Coagulation), Renal failure
HeparinActive bleeding, HIT (Heparin-induced thrombocytopenia)
WarfarinPregnancy, severe liver disease, recent surgery
DabigatranSevere renal impairment
RivaroxabanActive bleeding, liver disease

8. Drug Interactions

DrugInteracting DrugEffect
WarfarinNSAIDs, AspirinIncreased bleeding risk
HeparinThrombolytics (tPA)Increased risk of hemorrhage
DabigatranRifampinDecreased anticoagulant effect
RivaroxabanKetoconazoleIncreased anticoagulant effect
Vitamin KWarfarinReverses anticoagulant effect

9. Side Effects

Drug ClassCommon Side Effects
Vitamin KFlushing, dizziness, allergic reactions
Tranexamic AcidNausea, diarrhea, muscle cramps
HeparinBleeding, thrombocytopenia
WarfarinBleeding, skin necrosis
DabigatranDyspepsia, bleeding
RivaroxabanBleeding, liver dysfunction

10. Adverse Effects & Toxicity

  • Vitamin K Overdose: Rare, but excessive clotting.
  • Heparin Overdose: Hemorrhage, Heparin-Induced Thrombocytopenia (HIT).
  • Warfarin Toxicity: Life-threatening bleeding (requires Vitamin K or FFP as an antidote).
  • Dabigatran/Rivaroxaban Toxicity: Severe bleeding (treated with Idarucizumab for Dabigatran and Andexanet alfa for Factor Xa inhibitors).

11. Role of the Nurse

Before Administration

Assess:

  • Baseline clotting studies (PT, INR, aPTT, Platelet count)
  • History of bleeding disorders
  • Renal and liver function tests

During Administration

Monitor:

  • Signs of bleeding (hematuria, melena, epistaxis)
  • PT/INR for warfarin patients (keep INR 2-3)
  • aPTT for heparin therapy (maintain 1.5-2.5 times normal value)

After Administration

Evaluate:

  • Therapeutic response (controlled bleeding or clot prevention)
  • Monitor for side effects (bruising, bleeding, hypotension)

Patient Education

  • Avoid excessive green leafy vegetables (for warfarin users)
  • Report unusual bleeding, dark stools, or bruising
  • Regular INR testing for warfarin therapy
  • Avoid NSAIDs and aspirin unless prescribed
  • Do not stop anticoagulants suddenly without consulting a doctor.

Antiplatelets & Thrombolytics:

1. Introduction

  • Antiplatelets are drugs that prevent platelet aggregation and thrombus formation in arteries, reducing the risk of heart attack and stroke.
  • Thrombolytics (Fibrinolytics) are drugs that dissolve existing blood clots by breaking down fibrin, used in emergency situations like myocardial infarction (MI) and ischemic stroke.

2. Classification of Antiplatelets & Thrombolytics

A. Antiplatelets

ClassExamplesMechanism of Action
Cyclooxygenase (COX) InhibitorsAspirinInhibits thromboxane A2 (TXA2) synthesis, preventing platelet aggregation
ADP Receptor AntagonistsClopidogrel, Ticagrelor, PrasugrelBlock P2Y12 receptors, reducing platelet activation
Glycoprotein IIb/IIIa InhibitorsAbciximab, Eptifibatide, TirofibanPrevent platelet adhesion and aggregation
Phosphodiesterase InhibitorsDipyridamole, CilostazolIncrease cAMP levels, inhibiting platelet aggregation

B. Thrombolytics (Fibrinolytics)

ClassExamplesMechanism of Action
Tissue Plasminogen Activators (tPAs)Alteplase, Reteplase, TenecteplaseConvert plasminogen to plasmin, dissolving fibrin clots
Streptokinase & UrokinaseStreptokinase, UrokinaseActivate plasminogen to plasmin, breaking down clots

3. Composition of Antiplatelets & Thrombolytics

DrugActive Ingredient
AspirinAcetylsalicylic acid
ClopidogrelClopidogrel bisulfate
AbciximabMonoclonal antibody against GP IIb/IIIa
AlteplaseRecombinant tPA
StreptokinaseEnzyme from Streptococci

4. Mechanism of Action

A. Antiplatelets

  • Aspirin: Inhibits COX-1, preventing thromboxane A2 (TXA2) formation.
  • Clopidogrel: Irreversibly inhibits P2Y12 receptors, preventing platelet activation.
  • Glycoprotein IIb/IIIa inhibitors: Block platelet adhesion to fibrinogen.
  • Dipyridamole: Increases cAMP levels, inhibiting platelet aggregation.

B. Thrombolytics

  • Alteplase (tPA): Converts plasminogen into plasmin, breaking down fibrin clots.
  • Streptokinase: Forms an activator complex with plasminogen to degrade clots.
  • Urokinase: Directly activates plasminogen to dissolve fibrin.

5. Dosage and Routes of Administration

DrugDosageRoute
Aspirin75–325 mg dailyOral
Clopidogrel75 mg dailyOral
Ticagrelor90 mg twice dailyOral
AbciximabIV bolus: 0.25 mg/kg, infusion 0.125 µg/kg/minIV
Alteplase (tPA)0.9 mg/kg IV over 60 minIV
Streptokinase1.5 million IU over 1 hourIV

6. Indications

A. Antiplatelets

  • Prevention of Myocardial Infarction (MI)
  • Ischemic Stroke Prevention
  • Acute Coronary Syndrome (ACS)
  • Post-stent Placement
  • Peripheral Arterial Disease (PAD)

B. Thrombolytics

  • Acute Myocardial Infarction (STEMI)
  • Ischemic Stroke (within 4.5 hours)
  • Massive Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT) with severe symptoms

7. Contraindications

DrugContraindications
AspirinPeptic ulcer, bleeding disorders, asthma
ClopidogrelActive bleeding, liver disease
Glycoprotein IIb/IIIa InhibitorsRecent surgery, thrombocytopenia
Alteplase (tPA)Active bleeding, recent stroke, intracranial hemorrhage
StreptokinaseRecent streptococcal infection (due to antibodies)

8. Drug Interactions

DrugInteracting DrugEffect
AspirinWarfarin, NSAIDsIncreased bleeding risk
ClopidogrelProton pump inhibitors (PPIs)Reduced effectiveness
AbciximabAnticoagulantsIncreased risk of bleeding
AlteplaseAntiplateletsSynergistic bleeding risk
StreptokinaseHeparinIncreased risk of hemorrhage

9. Side Effects

Drug ClassCommon Side Effects
AspirinGI bleeding, tinnitus, nausea
ClopidogrelBleeding, diarrhea, rash
Glycoprotein IIb/IIIa InhibitorsThrombocytopenia, hypotension
Alteplase (tPA)Bleeding, allergic reactions
StreptokinaseHypotension, fever, bleeding

10. Adverse Effects & Toxicity

  • Aspirin Toxicity: Salicylism (tinnitus, metabolic acidosis)
  • Clopidogrel Overdose: Severe bleeding, hematoma
  • Glycoprotein IIb/IIIa Inhibitors: Thrombocytopenia, hypotension
  • Alteplase Toxicity: Intracranial hemorrhage
  • Streptokinase Hypersensitivity: Allergic reactions, anaphylaxis

Antidotes for Bleeding Complications:

  • Aspirin overdose: Activated charcoal, sodium bicarbonate (for acidosis)
  • Clopidogrel overdose: Platelet transfusion
  • Alteplase toxicity: Aminocaproic acid, fresh frozen plasma (FFP)
  • Streptokinase allergy: Corticosteroids, epinephrine

11. Role of the Nurse

Before Administration

Assess:

  • History of bleeding disorders, recent surgeries
  • Baseline platelet count, PT/INR, aPTT
  • Allergies (especially for Streptokinase)

During Administration

Monitor:

  • Signs of bleeding (gums, urine, stools)
  • Blood pressure (for hypotension with thrombolytics)
  • ECG monitoring in thrombolytic therapy

After Administration

Evaluate:

  • Therapeutic effect (prevented clot formation or dissolved clot)
  • Monitor for side effects (GI bleeding, bruising)

Patient Education

  • Aspirin & Clopidogrel: Take with food to prevent stomach irritation.
  • Report unusual bleeding, dark stools, or bruising immediately.
  • Avoid NSAIDs and alcohol while taking antiplatelets.
  • Thrombolytics: Avoid invasive procedures after administration.

Hypolipidemics (Lipid-Lowering Agents):

1. Introduction

Hypolipidemic drugs are used to lower lipid levels, primarily cholesterol and triglycerides, in order to prevent cardiovascular diseases like atherosclerosis, coronary artery disease (CAD), and stroke.


2. Classification of Hypolipidemic Drugs

ClassExamplesMechanism of Action
1. HMG-CoA Reductase Inhibitors (Statins)Atorvastatin, Rosuvastatin, SimvastatinInhibit HMG-CoA reductase, reducing cholesterol synthesis in the liver
2. Bile Acid SequestrantsCholestyramine, ColesevelamBind bile acids in the intestine, promoting excretion and reducing cholesterol
3. Fibric Acid Derivatives (Fibrates)Fenofibrate, GemfibrozilIncrease lipoprotein lipase activity, reducing triglycerides
4. Cholesterol Absorption InhibitorsEzetimibeInhibits cholesterol absorption in the small intestine
5. PCSK9 InhibitorsAlirocumab, EvolocumabIncrease LDL receptor availability, reducing LDL cholesterol
6. Omega-3 Fatty AcidsOmega-3 ethyl esters, Icosapent ethylReduce hepatic triglyceride production
7. Niacin (Vitamin B3)Niacin (Nicotinic Acid)Reduces LDL and triglycerides, increases HDL

3. Composition of Hypolipidemic Drugs

DrugActive Ingredient
AtorvastatinAtorvastatin calcium
FenofibrateFenofibrate micronized
EzetimibeEzetimibe
AlirocumabPCSK9 monoclonal antibody
NiacinNicotinic acid

4. Mechanism of Action

  • Statins: Block HMG-CoA reductase, reducing cholesterol production.
  • Bile Acid Sequestrants: Prevent bile acid reabsorption, forcing the liver to use cholesterol to make new bile acids.
  • Fibrates: Activate PPAR-α, increasing fatty acid oxidation and lowering triglycerides.
  • Ezetimibe: Blocks dietary cholesterol absorption in the intestines.
  • PCSK9 Inhibitors: Prevent LDL receptor degradation, increasing LDL clearance.
  • Omega-3 Fatty Acids: Reduce triglyceride production in the liver.
  • Niacin: Lowers LDL and triglycerides while increasing HDL by inhibiting lipolysis in adipose tissue.

5. Dosage and Routes of Administration

DrugDosageRoute
Atorvastatin10–80 mg once dailyOral
Rosuvastatin5–40 mg once dailyOral
Fenofibrate145 mg once dailyOral
Ezetimibe10 mg once dailyOral
Alirocumab75–150 mg every 2 weeksSubcutaneous (SC)
Niacin500–2000 mg/day (titrated)Oral
Omega-3 Fatty Acids2–4 g/dayOral

6. Indications

Drug ClassIndications
StatinsHypercholesterolemia, prevention of cardiovascular disease
Bile Acid SequestrantsHyperlipidemia, pruritus in bile acid disorders
FibratesHypertriglyceridemia, mixed dyslipidemia
Cholesterol Absorption InhibitorsAdjunct therapy for high cholesterol
PCSK9 InhibitorsFamilial hypercholesterolemia, resistant high LDL
NiacinHyperlipidemia, prevention of atherosclerosis
Omega-3 Fatty AcidsSevere hypertriglyceridemia

7. Contraindications

DrugContraindications
StatinsLiver disease, pregnancy, myopathy
Bile Acid SequestrantsBowel obstruction, hypertriglyceridemia
FibratesSevere renal/liver disease, gallbladder disease
EzetimibeSevere liver disease
PCSK9 InhibitorsAllergy to monoclonal antibodies
NiacinGout, peptic ulcer disease
Omega-3 Fatty AcidsFish/shellfish allergy

8. Drug Interactions

DrugInteracting DrugEffect
StatinsGrapefruit juiceIncreases toxicity risk
FenofibrateWarfarinIncreased bleeding risk
NiacinAntidiabetic drugsWorsens blood sugar control
EzetimibeStatinsIncreased liver enzyme levels
Omega-3 Fatty AcidsAntiplatelet drugsIncreased bleeding risk

9. Side Effects

Drug ClassCommon Side Effects
StatinsMuscle pain (myopathy), liver enzyme elevation
Bile Acid SequestrantsConstipation, bloating
FibratesGallstones, muscle pain
EzetimibeDiarrhea, liver dysfunction
PCSK9 InhibitorsInjection site reactions, flu-like symptoms
NiacinFlushing, itching, liver toxicity
Omega-3 Fatty AcidsFishy taste, burping

10. Adverse Effects & Toxicity

  • Statin Toxicity: Rhabdomyolysis (severe muscle breakdown) → Treat with IV fluids, Coenzyme Q10.
  • Niacin Overdose: Severe flushing, liver damage.
  • Fibrate Overdose: Severe muscle pain, kidney failure.
  • PCSK9 Inhibitor Hypersensitivity: Allergic reactions.
  • Bile Acid Sequestrant Toxicity: Vitamin deficiency (A, D, E, K) due to reduced absorption.

Management of Toxicity:

  • Statins: Stop the drug, monitor CK (creatine kinase) levels.
  • Niacin flushing: Take aspirin 30 minutes before.
  • Bile Acid Sequestrants: Supplement fat-soluble vitamins.
  • PCSK9 Inhibitor Reaction: Epinephrine for anaphylaxis.

11. Role of the Nurse

Before Administration

Assess:

  • Lipid profile (Total cholesterol, LDL, HDL, Triglycerides)
  • Liver function tests (ALT, AST)
  • Muscle pain complaints (for statins)

During Administration

Monitor:

  • Statins: Muscle pain, liver function tests.
  • Niacin: Flushing, liver enzymes.
  • Fibrates: Signs of gallstones, muscle pain.
  • Omega-3: Monitor for bleeding (especially if on anticoagulants).

After Administration

Evaluate:

  • Lipid levels (LDL ↓, HDL ↑, Triglycerides ↓)
  • Patient adherence to therapy
  • Adverse effects (muscle pain, GI issues)

Patient Education

  • Statins: Take at night (cholesterol synthesis peaks at night).
  • Avoid grapefruit juice with statins.
  • Niacin flushing can be reduced by taking aspirin 30 min before.
  • Increase fiber intake if using bile acid sequestrants.
  • Regular blood tests to monitor liver function.

Plasma Expanders & Treatment of Shock:

1. Introduction

Plasma expanders are intravenous fluids used to increase blood volume in cases of hypovolemia, such as in shock, severe dehydration, burns, and hemorrhage. They work by drawing fluid into the vascular compartment, maintaining circulatory stability.

Shock: Definition & Types

Shock is a life-threatening condition in which blood flow to organs is inadequate, leading to organ dysfunction and failure. It is classified into:

  1. Hypovolemic Shock: Due to fluid or blood loss (e.g., hemorrhage, burns).
  2. Cardiogenic Shock: Due to heart failure (e.g., myocardial infarction).
  3. Distributive Shock:
    • Septic Shock: Due to severe infection.
    • Neurogenic Shock: Due to spinal cord injury.
    • Anaphylactic Shock: Due to severe allergic reaction.
  4. Obstructive Shock: Due to blockage of blood flow (e.g., pulmonary embolism, cardiac tamponade).

2. Classification of Plasma Expanders

TypeExamplesMechanism of Action
1. CrystalloidsNormal saline (0.9% NaCl), Ringer’s lactate (RL)Provide electrolyte balance and hydration
2. ColloidsAlbumin, Dextran, Hydroxyethyl starch (HES), GelatinRetain fluid in the intravascular space by increasing oncotic pressure
3. Blood ProductsWhole blood, Fresh Frozen Plasma (FFP), Packed RBCsRestore lost blood components and improve oxygen-carrying capacity

3. Composition of Plasma Expanders

Plasma ExpanderMain Components
Normal Saline (NS)Sodium chloride (0.9%)
Ringer’s Lactate (RL)Sodium, Potassium, Calcium, Lactate
Albumin (5%, 25%)Human albumin
Dextran 40, 70Polysaccharides
Hydroxyethyl Starch (HES)Synthetic polymer
Gelatin (Gelofusine, Haemaccel)Protein-derived colloid

4. Mechanism of Action

  • Crystalloids: Increase intravascular volume by direct infusion, but can rapidly shift to the interstitial space.
  • Colloids: Maintain intravascular volume for longer periods by exerting oncotic pressure, pulling fluid into the blood vessels.
  • Blood Products: Improve oxygen transport (RBCs), coagulation (FFP, platelets), and volume.

5. Dosage & Routes of Administration

Plasma ExpanderDosageRoute
Normal Saline500–1000 mL over 30-60 minIV
Ringer’s Lactate500–1000 mL over 30-60 minIV
Albumin 5%250–500 mL IV over 1 hourIV
Dextran 40500–1000 mL over 4–6 hoursIV
HES (6%)500 mL over 30 minIV
FFP10–15 mL/kgIV

6. Indications

ConditionPlasma Expander Used
Hypovolemic ShockNormal Saline, Ringer’s Lactate, Albumin
Septic ShockColloids (Albumin, Dextran), Crystalloids
BurnsRinger’s Lactate, Albumin
HemorrhageBlood transfusion, FFP, Dextran
Anaphylactic ShockCrystalloids, Epinephrine
Neurogenic ShockColloids, Vasopressors

7. Contraindications

Plasma ExpanderContraindications
Normal SalineSevere kidney disease (risk of hypernatremia)
Ringer’s LactateLiver disease (impaired lactate metabolism)
AlbuminSevere heart failure (fluid overload risk)
DextranKidney failure, bleeding disorders
HESSepsis, renal failure

8. Drug Interactions

Plasma ExpanderInteracting DrugEffect
Normal SalineDiureticsMay cause dehydration
DextranAnticoagulantsIncreased bleeding risk
AlbuminACE inhibitorsHypotension risk
HESNSAIDsIncreased kidney damage

9. Side Effects

Plasma ExpanderCommon Side Effects
Normal SalineHypernatremia, fluid overload
Ringer’s LactateHyperkalemia, metabolic alkalosis
AlbuminAllergic reaction, fluid overload
DextranBleeding risk, kidney damage
HESAnaphylaxis, renal dysfunction

10. Adverse Effects & Toxicity

  • Crystalloids: Edema, electrolyte imbalance.
  • Colloids: Volume overload, allergic reactions.
  • Dextran Toxicity: Increased bleeding risk, kidney dysfunction.
  • HES Toxicity: Severe renal impairment, coagulation defects.

Management of Toxicity:

  • Stop infusion immediately.
  • Administer diuretics for fluid overload.
  • Provide supportive care (oxygen, dialysis if needed).

11. Treatment of Shock

General Management:

Identify the cause of shock
Maintain airway and oxygenation (O2 therapy, intubation if needed)
Restore circulation using IV fluids & vasopressors

Specific Management Based on Type of Shock

Type of ShockTreatment
Hypovolemic ShockCrystalloids (NS, RL), Colloids (Albumin), Blood transfusion
Cardiogenic ShockInotropes (Dopamine, Dobutamine), Diuretics, Oxygen
Septic ShockIV fluids (Crystalloids, Albumin), Antibiotics, Vasopressors
Neurogenic ShockIV fluids, Vasopressors (Norepinephrine)
Anaphylactic ShockEpinephrine, IV fluids, Antihistamines

12. Role of the Nurse

Before Administration

Assess:

  • Blood pressure, heart rate
  • Oxygen saturation
  • Fluid status (dehydration, edema)

During Administration

Monitor:

  • Vital signs (BP, HR, RR)
  • Urine output (kidney function)
  • Signs of fluid overload (shortness of breath, swelling)

After Administration

Evaluate:

  • Improved BP & perfusion
  • Resolution of shock symptoms
  • Watch for side effects (allergic reactions, overload)

Patient Education

  • Avoid excessive fluid intake if at risk for overload.
  • Report swelling or breathing difficulty immediately.
  • Regular monitoring for electrolyte imbalances.

Nurses’ Role and Responsibilities in Drugs Used for Cardiovascular System and Blood Disorders

1. Introduction

Nurses play a critical role in administering, monitoring, and educating patients about cardiovascular and hematologic medications. Their responsibilities include ensuring safety, preventing complications, and promoting adherence to treatment.


2. Common Drugs Used in Cardiovascular and Blood Disorders

Drug ClassExamplesIndications
1. AntihypertensivesAmlodipine, Lisinopril, Losartan, MetoprololHypertension, heart failure
2. AntiarrhythmicsAmiodarone, Lidocaine, DigoxinArrhythmias (AF, VT)
3. AntiplateletsAspirin, Clopidogrel, TicagrelorMI, Stroke prevention
4. AnticoagulantsHeparin, Warfarin, Dabigatran, RivaroxabanDVT, PE, AF, Stroke prevention
5. ThrombolyticsAlteplase (tPA), StreptokinaseMI, Ischemic Stroke, PE
6. HypolipidemicsAtorvastatin, RosuvastatinHigh cholesterol, CAD prevention
7. VasodilatorsNitroglycerin, HydralazineAngina, Heart failure
8. DiureticsFurosemide, HydrochlorothiazideHypertension, Edema, CHF
9. InotropesDopamine, DobutamineHeart failure, Shock
10. Erythropoiesis-Stimulating AgentsErythropoietin, DarbepoetinAnemia due to CKD, Chemotherapy
11. Iron SupplementsFerrous sulfate, Iron dextranIron deficiency anemia
12. Vitamin B12/Folic AcidCyanocobalamin, Folic AcidPernicious anemia, Megaloblastic anemia

3. Nurses’ Responsibilities in Drug Administration

A. Before Administration

Assess patient’s baseline status:

  • BP & HR for cardiovascular drugs
  • Bleeding risk for anticoagulants & antiplatelets
  • Lipid profile for statins
  • Kidney/liver function for drug metabolism

Check laboratory values:

  • PT/INR (Warfarin)
  • aPTT (Heparin)
  • Electrolytes (Diuretics, Digoxin)
  • Renal function (Creatinine, GFR) for ACE inhibitors & diuretics

Ensure correct dose and route:

  • Antihypertensives: Oral or IV, depending on severity
  • Diuretics: IV in emergency, Oral for maintenance
  • Thrombolytics: IV bolus + infusion
  • Anticoagulants: IV Heparin, Oral Warfarin

Check for contraindications:

  • Beta-blockers: Avoid in asthma/COPD
  • ACE inhibitors: Avoid in pregnancy
  • Thrombolytics: Avoid in recent surgery, bleeding disorders
  • Statins: Avoid in liver disease

Obtain informed consent (if required for high-risk drugs like thrombolytics).


B. During Administration

Monitor vital signs:

  • BP, HR, ECG (Antihypertensives, Antiarrhythmics)
  • Oxygen saturation, perfusion (Vasodilators, Inotropes)
  • Signs of bleeding (Anticoagulants, Thrombolytics)

Administer correctly:

  • IV Anticoagulants: Use infusion pumps for accuracy.
  • Sublingual Nitroglycerin: Administer under tongue & monitor BP.
  • Diuretics: Administer in the morning to avoid nocturia.

Observe for immediate reactions:

  • Statins: Muscle pain (rhabdomyolysis)
  • ACE inhibitors: Cough, angioedema
  • Beta-blockers: Bradycardia, hypotension
  • Thrombolytics: Severe bleeding

Prevent complications:

  • Administer fluids with diuretics to prevent dehydration.
  • Monitor K+ levels in patients on diuretics & ACE inhibitors.
  • Use antidotes when needed:
    • Protamine sulfate for Heparin overdose.
    • Vitamin K for Warfarin overdose.
    • Idarucizumab for Dabigatran toxicity.
    • Aminocaproic acid for thrombolytic bleeding.

C. After Administration

Evaluate effectiveness:

  • BP control (Antihypertensives)
  • Clot resolution (Thrombolytics, Anticoagulants)
  • Reduced chest pain (Nitroglycerin)
  • Improved oxygenation (Diuretics, Inotropes)
  • Increased hemoglobin (Iron, Erythropoietin)

Monitor for side effects:

  • Statins: Muscle pain, liver dysfunction
  • Anticoagulants: Bleeding gums, black stools
  • Diuretics: Dehydration, low K+ or Na+
  • Beta-blockers: Fatigue, bradycardia
  • ACE inhibitors: Persistent cough

Educate the patient:

  • Do not stop medications suddenly (especially beta-blockers, anticoagulants).
  • Monitor BP & HR daily (Hypertension & Heart failure patients).
  • Dietary restrictions:
    • Limit salt intake (For hypertension).
    • Avoid grapefruit (For statins).
    • Increase potassium-rich foods (For diuretics).
    • Avoid leafy greens in excess (For Warfarin patients).
  • Report signs of bleeding (easy bruising, dark stools).
  • Avoid NSAIDs & Aspirin unless prescribed (increased bleeding risk).

4. Emergency Management in Cardiovascular Drugs

ComplicationEmergency DrugNursing Management
Severe Bradycardia (from Beta-blockers, CCBs, Digoxin)Atropine, EpinephrineIV fluids, oxygen, monitor ECG
Hypertensive Crisis (from missed antihypertensive dose)IV Nitroprusside, LabetalolContinuous BP monitoring
Severe Bleeding (from Anticoagulants, Thrombolytics)Fresh Frozen Plasma, Vitamin K, Protamine SulfateStop drug, transfusion if needed
Rhabdomyolysis (from Statins)IV Fluids, Dialysis if neededMonitor CK levels, stop statin
Hypokalemia (from Diuretics)Potassium supplementsECG monitoring
Published
Categorized as BSC - SEM 3 - PHARMACOLOGY, Uncategorised